Login to Your Account



Other News To Note


Tuesday, April 12, 2011
RegeneRx Biopharmaceuticals Inc., of Rockville, Md., said researchers found that a fragment of Tbeta4 has the ability to inhibit a type of liver cell responsible for fibrosis and scar formation by blocking the binding of AKT to actin. Those data make possible the development of a therapeutic that can specifically identify and target cells responsible for the excessive scarring seen in liver diseases such as cirrhosis, as well as potential pathologies of the lungs, kidneys and other organs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription